Cinctive Capital Management LP Takes Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Cinctive Capital Management LP bought a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 273,959 shares of the biotechnology company's stock, valued at approximately $2,082,000. Cinctive Capital Management LP owned approximately 0.13% of BioCryst Pharmaceuticals as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in BCRX. Counterweight Ventures LLC increased its stake in shares of BioCryst Pharmaceuticals by 591.7% in the third quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company's stock valued at $710,000 after buying an additional 79,884 shares in the last quarter. XTX Topco Ltd grew its holdings in BioCryst Pharmaceuticals by 299.0% during the 2nd quarter. XTX Topco Ltd now owns 156,946 shares of the biotechnology company's stock worth $970,000 after acquiring an additional 117,607 shares during the last quarter. Seven Eight Capital LP increased its position in BioCryst Pharmaceuticals by 1,407.1% in the 2nd quarter. Seven Eight Capital LP now owns 169,612 shares of the biotechnology company's stock valued at $1,048,000 after acquiring an additional 158,358 shares in the last quarter. Rice Hall James & Associates LLC raised its stake in shares of BioCryst Pharmaceuticals by 4.0% in the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company's stock worth $16,444,000 after acquiring an additional 84,102 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 1,058.1% in the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company's stock valued at $3,127,000 after purchasing an additional 375,890 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

Analysts Set New Price Targets

BCRX has been the topic of several recent research reports. JMP Securities raised their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a "market outperform" rating in a report on Tuesday, August 6th. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Needham & Company LLC reissued a "buy" rating and issued a $14.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Barclays upped their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $15.60.

BioCryst Pharmaceuticals Stock Down 2.2 %

BioCryst Pharmaceuticals stock traded down $0.16 during midday trading on Tuesday, reaching $7.22. The stock had a trading volume of 896,152 shares, compared to its average volume of 2,887,843. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $8.88. The firm's fifty day simple moving average is $7.59 and its 200-day simple moving average is $7.32.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07). The business had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. During the same quarter last year, the firm earned ($0.19) EPS. BioCryst Pharmaceuticals's revenue for the quarter was up 35.1% compared to the same quarter last year. On average, analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.